In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Exploring Extractable and Leachable Testing Strategies for Parenterals
Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Elevating Medication Adherence and Clinical Outcomes with Connected Drug Delivery
Publications, Pharmaceutical, Product Solutions, Drug Delivery Innovations, Brand Differentiation, Market Insights

Aptar Pharma Injectable Expansion – Capacity, Capabilities and Partnership
Publications, Pharmaceutical, Market Insights, Product Solutions

Injectable Primary Packaging support compliance with Annex 1 Revision
Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions